Cover Image
市場調查報告書

Ligand Pharmaceuticals, Inc.:產品平台分析

Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224558
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
Ligand Pharmaceuticals, Inc.:產品平台分析 Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日期: 2016年07月13日 內容資訊: 英文 59 Pages
簡介

本報告網羅Ligand Pharmaceuticals, Inc.的醫藥品的開發趨勢,提供您企業概要,R&D的對象範圍,各開發階段的開發平台狀況,藥物簡介,近幾年的企業相關新聞等。

Ligand Pharmaceuticals, Inc.概要

  • 公司概要
  • 主要資訊
  • 主要資料

Ligand Pharmaceuticals, Inc.:R&D概要

  • 主要的目標範圍

Ligand Pharmaceuticals, Inc.:開發平台評估

  • 開發中產品:各開發階段
  • 單劑產品
  • 聯盟產品
  • 轉出授權產品

Ligand Pharmaceuticals, Inc.:開發中產品概況

  • 開發後期
    • 第三階段產品/聯合治療模式
  • 臨床實驗階段
    • 第二階段產品/聯合治療模式
    • 第一階段產品/聯合治療模式
  • 開發初期
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式
  • 開發階段不明
    • 開發階段不明的產品/聯合治療模式

Ligand Pharmaceuticals, Inc.:藥物簡介

  • clopidogrel bisulfate
  • MB-07133
  • aplindore fumarate
  • MB-07803
  • budesonide
  • LGD-4033
  • LGD-6972
  • pradefovir mesylate
  • Drug Targeting JAK3
  • Drug to Inhibit CCR1 for Oncology
  • Enterocyte-Directed DGAT-1 Inhibitor Program
  • IRAK4 Program
  • LG-5640
  • LG-7455
  • LG-7501
  • LGD-3437
  • PS-031291
  • Small Molecule to Inhibit CRTH2 for Inflammation
  • Small Molecules to Inhibit EPO Receptor for Anemia
  • tanaproget
  • Thyroid Receptor-Beta Agonist Program
  • fosphenytoin sodium
  • Undisclosed Anti-Inflammatory Program

Ligand Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Ligand Pharmaceuticals, Inc.:最近的開發平台趨勢

Ligand Pharmaceuticals, Inc.:暫停中的計劃

Ligand Pharmaceuticals, Inc.:中止開發的產品

Ligand Pharmaceuticals, Inc.:企業發表

Ligand Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08088CDB

Summary

Global Markets Direct's, 'Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Ligand Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Ligand Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Ligand Pharmaceuticals, Inc.
  • The report provides overview of Ligand Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Ligand Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Ligand Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Ligand Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ligand Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ligand Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Ligand Pharmaceuticals, Inc. Snapshot
    • Ligand Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Ligand Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Ligand Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Ligand Pharmaceuticals, Inc. - Pipeline Products Glance
    • Ligand Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Ligand Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Ligand Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Ligand Pharmaceuticals, Inc. - Drug Profiles
    • lasofoxifene tartrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • clopidogrel bisulfate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • aplindore fumarate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pradefovir mesylate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MB-07133
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LGD-6972
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Inhibit JAK3 for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LG-7455
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LGD-3437
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LGD-7501
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PS-031291
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize CCR1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate Glucokinase for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ligand Pharmaceuticals, Inc. - Pipeline Analysis
    • Ligand Pharmaceuticals, Inc. - Pipeline Products by Target
    • Ligand Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Ligand Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Ligand Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Ligand Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Ligand Pharmaceuticals, Inc. - Dormant Projects
  • Ligand Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • adipiplon
      • clopidogrel bisulfate
      • LGD-5552
      • managlinat dialanetil
      • NGD-2000-1
      • NGD-91-1
      • NGD-91-2
      • NGD-91-3
      • NGD-94-1
      • NGD-94-4
      • NGD-96-1
      • NGD-97-1
      • Vanilloid Receptor-1 Program
  • Ligand Pharmaceuticals, Inc. - Company Statement
  • Ligand Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Ligand Pharmaceuticals, Inc., Key Information
  • Ligand Pharmaceuticals, Inc., Key Facts
  • Ligand Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Ligand Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Ligand Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Ligand Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • Ligand Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Ligand Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016
  • Ligand Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Ligand Pharmaceuticals, Inc. - Pre-Registration, 2016
  • Ligand Pharmaceuticals, Inc. - Phase III, 2016
  • Ligand Pharmaceuticals, Inc. - Phase II, 2016
  • Ligand Pharmaceuticals, Inc. - Phase I, 2016
  • Ligand Pharmaceuticals, Inc. - Preclinical, 2016
  • Ligand Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Ligand Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Ligand Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Ligand Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Ligand Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • Ligand Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • Ligand Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016
  • Ligand Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Ligand Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • Ligand Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Ligand Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Ligand Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • Ligand Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016
  • Ligand Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016
  • Ligand Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Ligand Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Ligand Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top